Live Biotherapeutic Products and Microbiome Manufacturing Market

Characterized by a rapidly growing pipeline and the increasing demand for effective therapeutic interventions, outsourcing of certain manufacturing operations has emerged as a viable option for various microbiome therapeutic developers

Roots Analysis is pleased to announce the publication of its recent study, titled, “Live Biotherapeutic Products and Microbiome Manufacturing Market, 2022–2035”.

The report features an extensive study on the in- house and contract manufacturing organizations within the microbiome industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:
 A detailed overview of the overall landscape of companies offering contract manufacturing services for the development of microbiome therapeutics.
 A detailed landscape of the live biotherapeutic products and microbiome manufacturing facilities established across key geographical regions (North America, Europe and Asia-Pacific).
 An in-depth company competitiveness analysis of microbiome manufacturing service providers.
 Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics.
 A list of nearly 70 microbiome-focused drug developers that are likely to partner with manufacturers engaged in this domain.
 A review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021).
 An analysis of recent developments within the microbiome manufacturing industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.